Basilea Presents New Research Data On BAL27862
Basilea has presents new research data on its anti-tumor drug candidate BAL27862 at the international conference on Molecular Targets and Cancer Therapeutics in Boston (MA). The new data
The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
As part of the agreement, Asuragen will pursue CE marked-IVD registration in Europe and regulatory clearance in the US. The diagnostic test will then be distributed by Life